Brilliant Blue has been researched along with Hyperplasia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brophy, C; Cheung-Flynn, J; Hocking, KM; Komalavilas, P; Li, FD; Luo, W | 1 |
| Brophy, C; Cheung-Flynn, J; Hocking, K; Komalavilas, P; Osgood, MJ; Sexton, K; Song, J; Voskresensky, I | 1 |
2 other study(ies) available for Brilliant Blue and Hyperplasia
| Article | Year |
|---|---|
Brilliant blue FCF is a nontoxic dye for saphenous vein graft marking that abrogates response to injury.
Topics: Animals; Aorta; Benzenesulfonates; Calcium Signaling; Cells, Cultured; Coloring Agents; Cytoprotection; Female; Human Umbilical Vein Endothelial Cells; Humans; Hyperplasia; In Vitro Techniques; Male; Neointima; Organ Culture Techniques; Purinergic P2X Receptor Antagonists; Rats, Sprague-Dawley; Receptors, Purinergic P2X7; Saphenous Vein; Swine; Vascular Grafting; Vascular System Injuries; Vasoconstriction | 2016 |
Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasia.
Topics: Animals; Benzenesulfonates; Cell Line; Cell Movement; Cell Proliferation; Coloring Agents; Humans; Hyperplasia; Jugular Veins; Models, Animal; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neointima; Organ Culture Techniques; Purinergic P2X Receptor Antagonists; Rabbits; Rats; Receptors, Purinergic P2X7; Saphenous Vein; Signal Transduction; Time Factors; Tissue and Organ Harvesting | 2016 |